Clinical Trials | April 14, 2026
AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial
Highlights Mirvetuximab-based regimen promise
Highlights Mirvetuximab-based regimen promise
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
The license is valid for five years, effective from April 9, 2026
Integrated multidisciplinary model positions Hyderabad as a growing referral hub for advanced pediatric care
On-site medical room brings preventive care, routine consultations, and diagnostics closer to residents
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
These surgeries involve no bone cuts, minimal surgical trauma, smaller incisions and significantly reduced blood loss
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
The company says the platform offers improved manufacturability and functional advantages
Subscribe To Our Newsletter & Stay Updated
